Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 310

1.

Regulatory Considerations for Antiretroviral Prophylaxis to Prevent HIV Acquisition.

Miller V, Grant RM.

Clin Pharmacol Ther. 2014 Aug;96(2):153-5. doi: 10.1038/clpt.2014.114.

PMID:
25056397
[PubMed - in process]
2.

PMM.56 How do we screen our pregnant women for alcohol use?

Palaniappan S, Miller V.

Arch Dis Child Fetal Neonatal Ed. 2014 Jun;99 Suppl 1:A141. doi: 10.1136/archdischild-2014-306576.411.

PMID:
25021056
[PubMed - in process]
3.

PLD.52 Management and outcome of patients with Pre-labour Spontaneous rupture of membranes.

Annamraju H, Karnad R, Benson C, Miller V.

Arch Dis Child Fetal Neonatal Ed. 2014 Jun;99 Suppl 1:A122. doi: 10.1136/archdischild-2014-306576.351.

PMID:
25020992
[PubMed - in process]
4.

HIV and Hepatitis C Virus Infection in the United States: Whom and How to Test.

Panneer N, Lontok E, Branson BM, Teo CG, Dan C, Parker M, Stekler JD, DeMaria A Jr, Miller V.

Clin Infect Dis. 2014 May 27. pii: ciu396. [Epub ahead of print]

PMID:
24867787
[PubMed - as supplied by publisher]
5.

Accelerating drug development through collaboration: the hepatitis C drug development advisory group.

Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V.

Clin Pharmacol Ther. 2014 Aug;96(2):162-5. doi: 10.1038/clpt.2014.113. Epub 2014 May 22.

PMID:
24853733
[PubMed - in process]
6.

A multitiered strategy of simulation training, kit consolidation, and electronic documentation is associated with a reduction in central line-associated bloodstream infections.

Allen GB, Miller V, Nicholas C, Hess S, Cordes MK, Fortune JB, Blondin J, Ashikaga T, Ricci M.

Am J Infect Control. 2014 Jun;42(6):643-8. doi: 10.1016/j.ajic.2014.02.014.

PMID:
24837115
[PubMed - in process]
7.

Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

Pirazzoli V, Nebhan C, Song X, Wurtz A, Walther Z, Cai G, Zhao Z, Jia P, de Stanchina E, Shapiro EM, Gale M, Yin R, Horn L, Carbone DP, Stephens PJ, Miller V, Gettinger S, Pao W, Politi K.

Cell Rep. 2014 May 22;7(4):999-1008. doi: 10.1016/j.celrep.2014.04.014. Epub 2014 May 9.

PMID:
24813888
[PubMed - in process]
Free Article
8.

Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles.

Munster M, Fremder E, Miller V, Ben-Tsedek N, Davidi S, Scherer SJ, Shaked Y.

PLoS One. 2014 Apr 21;9(4):e95983. doi: 10.1371/journal.pone.0095983. eCollection 2014.

PMID:
24752333
[PubMed - in process]
Free PMC Article
9.

Regoaling: a conceptual model of how parents of children with serious illness change medical care goals.

Hill DL, Miller V, Walter JK, Carroll KW, Morrison WE, Munson DA, Kang TI, Hinds PS, Feudtner C.

BMC Palliat Care. 2014 Mar 13;13(1):9. doi: 10.1186/1472-684X-13-9.

PMID:
24625345
[PubMed]
Free PMC Article
10.

Beneficial impact of antiretroviral therapy on non-AIDS mortality.

Miller V, Hodder S.

AIDS. 2014 Jan 14;28(2):273-4. doi: 10.1097/QAD.0000000000000079. No abstract available.

PMID:
24413312
[PubMed - in process]
11.

Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin.

Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B, Shaked Y.

Int J Cancer. 2014 Jul 15;135(2):270-81. doi: 10.1002/ijc.28678. Epub 2014 Jan 13.

PMID:
24347266
[PubMed - indexed for MEDLINE]
12.

Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.

Alishekevitz D, Bril R, Loven D, Miller V, Voloshin T, Gingis-Velistki S, Fremder E, Scherer SJ, Shaked Y.

Mol Cancer Ther. 2014 Jan;13(1):202-13. doi: 10.1158/1535-7163.MCT-13-0356. Epub 2013 Oct 22.

PMID:
24150126
[PubMed - in process]
13.

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V.

J Clin Oncol. 2013 Nov 1;31(31):3926-34. doi: 10.1200/JCO.2012.47.3983. Epub 2013 Oct 7.

PMID:
24101054
[PubMed - indexed for MEDLINE]
14.

Response to the letter of Kawada T on adiponectin and the metabolic syndrome.

Calton EK, Miller V, Soares MJ.

Eur J Clin Nutr. 2013 Aug;67(8):897. doi: 10.1038/ejcn.2013.105. Epub 2013 Jun 19. No abstract available.

PMID:
23778787
[PubMed - indexed for MEDLINE]
15.

Multisystem dysregulation in painful temporomandibular disorders.

Chen H, Nackley A, Miller V, Diatchenko L, Maixner W.

J Pain. 2013 Sep;14(9):983-96. doi: 10.1016/j.jpain.2013.03.011. Epub 2013 May 28.

PMID:
23721875
[PubMed - indexed for MEDLINE]
16.

Getting to normal: are we there yet?

Miller V, Horberg M.

AIDS. 2013 Mar 27;27(6):1027-8. doi: 10.1097/QAD.0b013e32835e39c6. No abstract available.

PMID:
23698066
[PubMed - indexed for MEDLINE]
17.

Goal setting with mothers in child development services.

Forsingdal S, St John W, Miller V, Harvey A, Wearne P.

Child Care Health Dev. 2014 Jul;40(4):587-96. doi: 10.1111/cch.12075. Epub 2013 May 13.

PMID:
23662628
[PubMed - in process]
18.

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set.

Houssaini A, Assoumou L, Miller V, Calvez V, Marcelin AG, Flandre P.

PLoS One. 2013;8(3):e59014. doi: 10.1371/journal.pone.0059014. Epub 2013 Mar 21.

PMID:
23555613
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, Ross J, Miller V, Ginsberg M, Zakowski MF, Kris MG, Ladanyi M, Rizvi N.

Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26.

PMID:
23533264
[PubMed - indexed for MEDLINE]
20.

Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy.

Lontok E, Mani N, Harrington PR, Miller V.

Clin Infect Dis. 2013 May;56(10):1466-70. doi: 10.1093/cid/cit025. Epub 2013 Jan 29.

PMID:
23362287
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk